ErbB 2 Pathway Activation upon Smad 4 Loss Promotes Lung Tumor Growth and Metastasis Graphical
暂无分享,去创建一个
Jianqiang Mao | Sung-Nam Cho | Nili Jin | Tenghui Chen | Chad J. Creighton | Farrah Kheradmand | Bindu Akkanti | Yiqun Zhang | C. Creighton | Yiqun Zhang | Ximing Tang | Jian Liu | F. DeMayo | Tenghui Chen | F. Kheradmand | Francesco J. DeMayo | Weiwen Long | Weiwen Long | B. Akkanti | Ximing Tang | Jian Liu | Nili Jin | Ignacio I. Wistub | J. Mao | Sung-Nam Cho
[1] C. Chai,et al. Role Of TTF‐1, CK20, And CK7 Immunohistochemistry for Diagnosis of Primary and Secondary Lung Adenocarcinoma , 2006, The Kaohsiung journal of medical sciences.
[2] R. Neve,et al. ERBB Receptor Regulation of ESX/ELF3 Promotes Invasion in BreastEpithelial Cells , 2010 .
[3] Takayuki Kosaka,et al. Expression profile-defined classification of lung adenocarcinoma shows close relationship with underlying major genetic changes and clinicopathologic behaviors. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] Ming-Tsan Lin,et al. Role of surgical intervention in managing gastrointestinal metastases from lung cancer. , 2011, World journal of gastroenterology.
[5] Philippe Soriano. Generalized lacZ expression with the ROSA26 Cre reporter strain , 1999, Nature Genetics.
[6] Karl J. Dykema,et al. Cancer-Type Regulation of MIG-6 Expression by Inhibitors of Methylation and Histone Deacetylation , 2012, PloS one.
[7] A. R. Thitoff,et al. Conditional deletion of Pten causes bronchiolar hyperplasia. , 2008, American journal of respiratory cell and molecular biology.
[8] A. Jemal,et al. Cancer statistics, 2014 , 2014, CA: a cancer journal for clinicians.
[9] A. Jemal,et al. Cancer Statistics, 2010 , 2010, CA: a cancer journal for clinicians.
[10] T. Mitsudomi,et al. Somatic in vivo alterations of the DPC4 gene at 18q21 in human lung cancers. , 1996, Cancer research.
[11] Ester Piek,et al. Role of Transforming Growth Factor-β Signaling in Cancer , 2000 .
[12] Shohei Koyama,et al. Loss of Lkb1 and Pten leads to lung squamous cell carcinoma with elevated PD-L1 expression. , 2014, Cancer cell.
[13] Zhaoyuan Fang,et al. Transdifferentiation of lung adenocarcinoma in mice with Lkb1 deficiency to squamous cell carcinoma , 2014, Nature Communications.
[14] S. Walker. Updates in non-small cell lung cancer. , 2008, Clinical journal of oncology nursing.
[15] A. Berns,et al. Cell of origin of lung cancer , 2010, Molecular oncology.
[16] P. Seeburg,et al. Codon‐improved Cre recombinase (iCre) expression in the mouse , 2002, Genesis.
[17] I. Wistuba,et al. The evolving genomic classification of lung cancer , 2013, The Journal of pathology.
[18] C. Deng,et al. Generation of Smad4/Dpc4 conditional knockout mice , 2002, Genesis.
[19] Kristofer C. Berrett,et al. Sox2 Cooperates with Lkb1 Loss in a Mouse Model of Squamous Cell Lung Cancer , 2014, Cell reports.
[20] M. Tsao,et al. Loss of Phosphatase and Tensin Homolog Protein Expression Is an Independent Poor Prognostic Marker in Lung Adenocarcinoma , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[21] T. Hogan,et al. Eastern Cooperative Oncology Group study 1879: mitotane and adriamycin in patients with advanced adrenocortical carcinoma. , 1991, Surgery.
[22] Hong Wu,et al. Pten inactivation accelerates oncogenic K-ras-initiated tumorigenesis in a mouse model of lung cancer. , 2008, Cancer research.
[23] S. Peters,et al. Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] Andrew D. Yates,et al. Athletics: Momentous sprint at the 2156 Olympics? , 2004, Nature.
[25] J. Komorowski,et al. Markers of Adenocarcinoma Characteristic of the Site of Origin: Development of a Diagnostic Algorithm , 2005, Clinical Cancer Research.
[26] M. Vangel,et al. Trastuzumab in the treatment of advanced non-small-cell lung cancer: is there a role? Focus on Eastern Cooperative Oncology Group study 2598. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] Susan E. Wert,et al. Early restriction of peripheral and proximal cell lineages during formation of the lung , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[28] M. Ladanyi,et al. Prevalence, Clinicopathologic Associations, and Molecular Spectrum of ERBB2 (HER2) Tyrosine Kinase Mutations in Lung Adenocarcinomas , 2012, Clinical Cancer Research.
[29] F. DeMayo,et al. Cre‐mediated recombination in mouse Clara cells , 2008, Genesis.
[30] Ming-Rong Wang,et al. Synergistic function of Smad4 and PTEN in suppressing forestomach squamous cell carcinoma in the mouse. , 2006, Cancer research.
[31] Yuh-Shan Jou,et al. Genomewide loss of heterozygosity and its clinical associations in non small cell lung cancer , 2005, International journal of cancer.
[32] L. Wang,et al. Expression of DPC4/Smad4 in non-small-cell lung carcinoma and its relationship with angiogenesis. , 2008, Neoplasma (Bratislava).
[33] Gary Box,et al. The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer . , 2008, Journal of medicinal chemistry.
[34] F. Liu. SMAD4/DPC4 and pancreatic cancer survival. Commentary re: M. Tascilar et al., The SMAD4 protein and prognosis of pancreatic ductal adenocarcinoma. Clin. Cancer Res., 7: 4115-4121, 2001. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[35] S. Sakashita,et al. Genes and pathology of non-small cell lung carcinoma. , 2014, Seminars in oncology.
[36] R. Bronson,et al. Evidence that MIG-6 is a tumor-suppressor gene , 2007, Oncogene.
[37] M. Meyerson,et al. The major lung cancer-derived mutants of ERBB2 are oncogenic and are associated with sensitivity to the irreversible EGFR/ERBB2 inhibitor HKI-272 , 2007, Oncogene.
[38] Toshio Kuroki,et al. Role of Smad4 (DPC4) inactivation in human cancer. , 2003, Biochemical and biophysical research communications.
[39] Steven J. M. Jones,et al. Comprehensive molecular profiling of lung adenocarcinoma , 2014, Nature.
[40] M. Groszer,et al. Cre/loxP‐mediated inactivation of the murine Pten tumor suppressor gene , 2002, Genesis.
[41] J. Jen,et al. TGF-&bgr; Signaling and the Role of Inhibitory Smads in Non-small Cell Lung Cancer , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[42] Yigong Shi,et al. A structural basis for mutational inactivation of the tumour suppressor Smad4 , 1997, Nature.
[43] O. Sansom,et al. HER2 overcomes PTEN (loss)-induced senescence to cause aggressive prostate cancer , 2011, Proceedings of the National Academy of Sciences.
[44] A. Ullrich,et al. Mig-6 Is a Negative Regulator of the Epidermal Growth Factor Receptor Signal , 2001, Biological chemistry.
[45] A. McCullough. Comprehensive genomic characterization of squamous cell lung cancers , 2013 .
[46] Gerald C. Chu,et al. SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression , 2011, Nature.
[47] S. Steinberg,et al. Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain. , 2008, Journal of the National Cancer Institute.
[48] S. Malkoski,et al. Role of PTEN in basal cell derived lung carcinogenesis , 2014, Molecular carcinogenesis.
[49] J. Massagué,et al. Smad transcription factors. , 2005, Genes & development.
[50] T. Mak,et al. Pten controls lung morphogenesis, bronchioalveolar stem cells, and onset of lung adenocarcinomas in mice. , 2007, The Journal of clinical investigation.
[51] T. Yoshimatsu,et al. Long-term survival after surgical resection of liver metastasis from lung cancer. , 2004, The Japanese journal of thoracic and cardiovascular surgery : official publication of the Japanese Association for Thoracic Surgery = Nihon Kyobu Geka Gakkai zasshi.
[52] Wendy Winckler,et al. Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2 , 2012, Proceedings of the National Academy of Sciences.
[53] C. Creighton,et al. COUP-TFII inhibits TGF-β-induced growth barrier to promote prostate tumorigenesis , 2012, Nature.